Akorn Completes Sale Following Bankruptcy Filing
US Firm Exits Chapter 11 Protection
Akorn aims for “long-term growth and a brighter future” after exiting Chapter 11 protection that it had filed for in May 2020. After completing the sale to its lenders, the company is now operating as a private entity under the legal name, Akorn Operating Company LLC.
You may also be interested in...
Mergers and acquisitions have long been a tool for value creation in the generics and biosimilars space. Even with the entire life sciences sector overwhelmed by the novel coronavirus pandemic, deals big and small continued in 2020.
As Apotex names its new US president and CEO, Akorn puts together a fresh board of directors following bankruptcy proceedings. Stada has made new appointments in Germany, while Siegfried makes significant changes in its leadership roles.
Japan’s Nippon Chemiphar has managed to reduce its rate of decline in pharmaceutical sales in the third quarter of FY21, on the back of well-performing recently-launched generics and group-wide structural reforms and cost reductions. The company is making no changes to its full-year forecast.